Furthermore, the persistence of leukemia-associated mutations, such as FLT3-ITD, NPM1, and CEBPA mutations, after the initial course of standard induction chemotherapy imparts a significantly increased risk of subsequent leukemic relapse and death (27–29). This evidence concerns the gene CEBPA and leukemia.